Last reviewed · How we verify
NCT05794100
Evaluating the Impact of Different Sugar Replacer Combinations on Gastrointestinal Tolerance
NA trial testing Acute intake of one of the products (active comparator 1 to 9) or Placebo comparator in Tolerance in 60 participants. Completed in 30 July 2022.
30 May 2022
Quick facts
| Lead sponsor | Mondelēz International, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | prevention |
| Enrollment | 60 |
| Start date | 11 October 2021 |
| Primary completion | 30 May 2022 |
| Estimated completion | 30 July 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Acute intake of one of the products (active comparator 1 to 9) or Placebo comparator
Conditions studied
- Tolerance — all drugs for Tolerance →
- Healthy Population — all drugs for Healthy Population →
Sponsor
Mondelēz International, Inc. — full company profile →
Who can join
Adults 18 to 55, any sex, with Tolerance or Healthy Population. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a randomized, double-blind, crossover trial aiming at evaluating the gastrointestinal tolerance of 3 sugar replacers mixes at 3 different doses. The investigators will also try to understand the factors that could explain the presence or absence of symptoms
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05794100
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Tolerance
Currently open trials in the same condition.
- NCT06189170 — Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients · EARLY_PHASE1 · recruiting
- NCT05644717 — Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD · Phase 4 · recruiting
- NCT05022420 — SAfety and TOlerance of the Biopsies in Auto-immune Rare dIseases · recruiting
- NCT06286488 — Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza · Phase 4 · active not recruiting
Other Mondelēz International, Inc. trials
Trials by the same sponsor.
- NCT07372482 — Evaluating the Impact of Fat and Sugar Replacer Blends on Gastrointestinal Tolerance in Biscuits · NA · completed
- NCT06479330 — Evaluating the Impact of Incremental Doses of a Sugar Replacer Blend on Gastrointestinal Tolerance in Chocolate · NA · completed
- NCT05827198 — Evaluating the Impact of Incremental Doses of a Sugar Replacer Blend on Gastrointestinal Tolerance in Candies · NA · unknown
- NCT03847701 — Cardio-metabolic and Inflammatory Impact of Starch Digestibility in Type 2 Diabetic Patients · NA · completed
- NCT03289494 — Evaluation of 2 Diets With Different Starch Digestibility Profiles on Daily Glycemic Profile, in T2D Patients · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05794100 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mondelēz International, Inc.
- Last refreshed: 3 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05794100.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing